TAKASI NAKAHARA

Last Updated :2023/02/02

Affiliations, Positions
Hiroshima University Hospital(Medical), Associate Professor or Lecturer
E-mail
nakaharahiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2007/04/01, JA Hiroshima General Hospital, MEDICAL DOCTOR
  • 2010/04/01, 2011/03/31, Hiroshima University, Hospital, Clinical Fellow
  • 2016/04/01, 2018/03/31, Hiroshima University, Hospital, Assistant Professor
  • 2017/12/01, 2018/03/31, Hiroshima University, Hospital, Clinical Lecturer
  • 2018/04/01, 2021/03/31, Hiroshima University, Hospital, Associate Professor

Educational Backgrounds

  • Tokushima University, 1999/04, 2005/03

Academic Degrees

  • Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine

Affiliated Academic Societies

  • The Japanese Society of Internal Medicine
  • The Japanese Society of Gastroenterology
  • Japan Gastroenterological Endoscopy Society
  • The Japan Society of Hepatology

Educational Activity

Course in Charge

  1. 2022, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2022, Undergraduate Education, Intensive, Introduction to clinical clerkship
  3. 2022, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2022, Undergraduate Education, Intensive, Practice of Medicine II
  5. 2022, Undergraduate Education, First Semester, Internal Medicine I

Research Activities

Academic Papers

  1. Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD, HEPATOLOGY COMMUNICATIONS, 6(7), 1527-1536, 202207
  2. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment, PLOS ONE, 17(1), 20220118
  3. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease, SCIENCE TRANSLATIONAL MEDICINE, 14(650), 20220622
  4. Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study, BMC GASTROENTEROLOGY, 22(1), 20220602
  5. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84(3), 391-399, 202203
  6. Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene, CASE REPORTS IN GASTROENTEROLOGY, 16(1), 110-115, 2022
  7. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 37(3), 592-599, 202203
  8. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study., Hepatology Research, 42, 1065-1072, 2012
  9. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients., Journal of Gastroenterology, 49(11), 1477-1488, 201411
  10. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31(5), 1009-1015, 201605
  11. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46(9), 944-948, 201608
  12. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51(11), 1073-1080, 201611
  13. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46(12), 1256-1263, 201611
  14. Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89(4), 665-671, 201704
  15. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52(3), 366-375, 201703
  16. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52(6), 746-753, 201706
  17. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, ONCOLOGY, 92(6), 335-346, 2017
  18. ★, Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease., Journal of Gastroenterology, 2017
  19. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients., Antivir Ther., 20170921
  20. Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS., Scientific Reports, 20170831
  21. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study., Journal of Gastroenterology, 20170816
  22. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy., PLoS One., 20170810
  23. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients., Journal of Medical Virology, 1963-1972, 201711
  24. Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia., Clinical Journal of Gastroenterology, 20170810
  25. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of Gastroenterology, 20170529
  26. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma., Hepatology Research, 20170520
  27. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury., Journal of Gastroenterology, 20170505
  28. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of Gastroenterology, 20170504
  29. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis., Hepatology Research, 20170324
  30. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones., Journal of Infection, 72(1), 91-102, 2016
  31. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), 20170810
  32. Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS, SCIENTIFIC REPORTS, 7, 20170831
  33. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, JOURNAL OF MEDICAL VIROLOGY, 89(11), 1963-1972, 201711
  34. Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia, CLINICAL JOURNAL OF GASTROENTEROLOGY, 10(4), 383-387, 201708
  35. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, JOURNAL OF GASTROENTEROLOGY, 52(12), 1252-1257, 201712
  36. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 201801
  37. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 48(1), 51-58, 201801
  38. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(2), 193-204, 201802
  39. ★, Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53(2), 269-280, 201802
  40. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48(4), 264-274, 201803
  41. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study, JOURNAL OF GASTROENTEROLOGY, 53(4), 548-556, 201804
  42. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis, ONCOLOGY, 94(4), 215-222, 2018
  43. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLOS ONE, 13(4), 20180403
  44. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial, BMC CANCER, 18, 20180604
  45. A case of primary hepatic angiosarcoma evaluated by contrast-enhanced ultrasonography, Jpn J Med Ultrasonics, 45(2), 215-221, 2018
  46. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice, HEPATOLOGY RESEARCH, 48(10), 814-820, 201809
  47. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33(10), 1780-1786, 201810
  48. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90(12), 1834-1840, 201812
  49. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study, JOURNAL OF GASTROENTEROLOGY, 53(11), 1216-1224, 201811
  50. Early experience of seven hepatocellular carcinoma cases treated with regorafenib, CLINICAL CASE REPORTS, 6(11), 2217-2223, 201811
  51. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25(12), 1555-1564, 201812
  52. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525, 48-61, 201812
  53. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(13), 1118-1130, 201812
  54. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23(3), 239-248, 2018
  55. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91(4), 650-658, 201904
  56. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54(3), 291-296, 201903
  57. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3(3), 348-355, 201903
  58. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23(8), 639-646, 2018
  59. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 53(8), 986-993, 2018
  60. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
  61. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100(7), 1123-1131, 201907
  62. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12(4), 341-346, 201908
  63. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 97(2), 75-81, 2019
  64. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy, SCIENTIFIC REPORTS, 9, 20190820
  65. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 34(8), 1390-1395, 201908
  66. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study., Antivir Ther., 2019
  67. Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS., 2019
  68. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., 2019
  69. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis., 2019
  70. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy., 2019
  71. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19(1), 20191024
  72. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55(2), 217-226, 202002
  73. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124, 202003
  74. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection, INTERNAL MEDICINE, 59(7), 941-944, 2020
  75. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients, LIVER CANCER, 9(2), 148-155, 202004
  76. Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(3), 421-427, 202006
  77. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 202005
  78. Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study, JGH OPEN, 4(3), 497-502, 202006
  79. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50(7), 885-888, 202007
  80. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(14), 202007
  81. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 202005
  82. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 202008
  83. Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study, HEPATOLOGY RESEARCH, 50(8), 955-965, 202008
  84. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 867-872, 202010
  85. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 839-843, 202010
  86. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection, BMC GASTROENTEROLOGY, 20(1), 20200925
  87. Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration, JOURNAL OF INFECTIOUS DISEASES, 222(7), 1165-1169, 20201001
  88. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 202011
  89. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50(11), 1234-1243, 202011
  90. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28(2), 400-409, 202102
  91. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222(12), 2061-2070, 20201215
  92. Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study, JGH OPEN, 5(2), 228-234, 202102
  93. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(1), 283-287, 202102
  94. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60(6), 829-837, 2021
  95. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein, LIVER CANCER, 10(2), 151-160, 202104
  96. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23, 2021
  97. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes, HEPATOLOGY COMMUNICATIONS, 5(4), 559-572, 202104
  98. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy, ONCOLOGY, 99(5), 327-335, 202104
  99. yRibavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 92(2), 210-218, 202002
  100. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559, 78-83, 20210625
  101. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23(1), 202101
  102. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease, DIAGNOSTICS, 10(8), 202008
  103. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 36(6), 1685-1693, 202106
  104. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
  105. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients, MEDICINE, 100(26), 20210702
  106. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib, INTERNAL MEDICINE, 60(13), 2047-2053, 2021
  107. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma, ONCOLOGY, 99(8), 507-517, 202107
  108. Clinical Outcomes of 2nd-and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma, ONCOLOGY, 99(8), 491-498, 202107
  109. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
  110. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28(9), 1304-1311, 202109
  111. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice, CANCERS, 13(16), 202108
  112. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab, MEDICINE, 100(42), 20211022
  113. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma, CANCERS, 14(2), 202201

Invited Lecture, Oral Presentation, Poster Presentation

  1. Efficacy of multiple therapeutic drug combination in the treatment of hepatic encephalopathy, JSH International Liver Conference, 2019/11/08, With Invitation, English, preprint
  2. Control of refractory ascites with administration of Tolvaptan supresses muscle mass reduction, International Liver Symposium 2019, 2019/02/09, Without Invitation, English, preprint
  3. Serum autotaxin levels is useful to evaluate fibrosis during entecavir therapy and to predict the development of hepatocellular carcinoma in patients with chronic Hepatitis B., 2019 International HBV Meeting, 2019/10/04, Without Invitation, English, preprint
  4. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells., 2019 International HBV Meeting, 2019/10/04, Without Invitation, English, preprint
  5. Efficacy of multiple therapeutic drug combination in the treatment of hepatic encephalopathy, 2019/10/02, Without Invitation, English, preprint
  6. Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, The Liver Meeting 2017, 2017/10/22, Without Invitation, English, other
  7. Association of TLL1 Polymorphism with Development of Hepatocellular Carcinoma after Hepatitis C Virus Eradication and Fibrosis Severity, THE LIVER MEETING 2018, 2018/11/10, Without Invitation, English, other
  8. "Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and TACE refractory", The Asian Pacific Association for the Study of the Liver, 2018/05/13, Without Invitation, English, other
  9. "Stereotactic body radiation therapy combined with transcatheter arterial che moembolization for small hepatocellular carcinoma.", The Asian Pacific Association for the Study of the Liver, 2018/05/13, Without Invitation, English, other
  10. "Experience of regorafenib treatment for the patients with hepatocellular car cinoma progressed after sorafenib", The Asian Pacific Association for the Study of the Liver, 2018/05/13, Without Invitation, English, other
  11. 薬剤性過敏性症候群(DIHS)により急性肝不全を来した1症例, 2016/11/17, Without Invitation, Japanese
  12. Japanese genetic study could not suggest the importance of the NTCP l ocus for HBV persistence, D.Miki, Nakahara T, APASL, 2016/02/20, Without Invitation, English
  13. Involvement of type 4 porphyromonas gingivalis in the progression of non-alcoholic fatty liver diseas, nakahara Takashi, AASLD, 2016/11/11, Without Invitation, English

Awards

  1. 2015, 第3回 肝臓と糖尿病研究会 研究奨励賞

Social Activities

History as Peer Reviews of Academic Papers

  1. 2017, Hematology research, Editor